Clinical trial
A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic…
NCT00136409 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00136409 |
|---|---|
| Title | A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML) |
| Official title | A Phase II Study of Gleevec (Imatinib Mesylate) In Patients With BCR-Negative Myeloproliferative Disorders Including Patients With Idiopathic Myelofibrosis With Myeloid Dysplasia or Chronic Myelomonocytic Leukemia |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Brigham and Women's Hospital Massachusetts General Hospital Novartis Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Myelofibrosis, Myeloid Metaplasia, Agnogenic Myeloid Metaplasia, Chronic Myelomonocytic Leukemia |
| Intervention type | Drug |
| Interventions | Imatinib mesylate |
| Enrollment | 34 |
| Start date | May 1, 2002 |
| Primary completion | Aug 1, 2005 |
| Completion | Dec 1, 2008 |
| First posted | Aug 29, 2005 |
| Last update posted | Dec 23, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: